Figure S1. Cytotoxic T lymphocyte antigen-4 (CTLA-4)-immunoglobulin (Ig) binds to dendritic cells (DCs) and down-regulates CD86 on both DCs and B cells in the draining lymph node after sensitization with dinitrofluorobenzene (DNFB). Groups of mice were treated with either CTLA-4-Ig or isotype control and sensitized with 0·5% DNFB the following day. Lymph node cells from the draining lymph node were stained with anti-human IgG1 and analysed by flow cytometry at days 3, 4 and 5 after sensitization for detection of binding of CTLA-4-Ig on lymph node cells. (A) %hIgG1+ cells of DCs gated as CD19T cell receptor (TCR)-βmajor histocompatibility complex II (MHC)II+CD11c+ cells 3, 4 and 5 days after sensitization. (B) %CD86+ cells of DCs. (C) Median fluorescence intensity (MFI) of CD86 phycoerythrin (PE) on CD19MHCII+CD11C+ cells. (D) %hIgG1+ cells of B cells gated as CD19+ cells. (E) %CD86+ cells of B cells gated as CD19+ cells. (F) MFI of CD86 PE on CD19+ cells. Data are depicted as mean ± standard error of the mean, *P < 0·05, **P < 0·01 and ***P < 0·001. ‘Grey box' : Isotype control-treated mice (hIgG1) (25 mg/kg); ‘black box' : CTLA-4-Ig-treated mice (25 mg/kg).


Figure S2. Cytotoxic T lymphocyte antigen-4 (CTLA-4)-immunoglobulin (Ig) treatment during challenge phase mediates a reduced release of interleukin (IL)-4 and macrophage inflammatory protein-2 (MIP-2). Donor mice were sensitized to dinitrofluorobenzene (DNFB) in the presence or absence of CTLA-4-Ig. After 5 days, cells from the draining lymph node were transferred to recipient mice which were treated with CTLA-4-Ig 24 h earlier where indicated. Mice were challenged 5 h later with DNFB and ear swelling measured 24 and 48 h later; 48 h after challenge homogenates of inflamed ear tissue were analysed for their content of IL-1β, IL-4, interferon gamma-induced protein (IP)-10 and MIP-2 (a). Ear swelling in the groups is shown in (b) after 24 h (upper) and as area under the curve (lower). +/−: CTLA-4-Ig treatment during sensitization phase alone; −/+: CTLA-4-Ig treatment during challenge phase alone; −/−: no treatment with CTLA-4-Ig. Data are depicted as mean ± standard error of the mean, *P < 0·05, **P < 0·01 and ***P < 0·001.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.